CoChat

Relation of Different Measures of Low-Density Lipoprotein Cholesterol to Risk of Coronary Artery Disease and Death in a Meta-Regression Analysis of Large-Scale Trials of Statin Therapy

Open access
Kizer, Jorge R., Madias, Christopher, Wilner, Brian, Vaughan, Carl J., Mushlin, Alvin I., Trushin, Paula, Gotto, Antonio M., Pasternak, Richard C. · 2010 · The American Journal of Cardiology
Cited by 52

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Multiple randomized controlled trials (RCTs) have established the efficacy of statins for prevention of cardiovascular disease. The benefits observed are often framed in terms of percent reductions in low-density lipoprotein cholesterol (LDL-C) from baseline or percent reduction between control and treatment groups, even though epidemiological data suggest that absolute inter-group difference in LDL-C (ΔLDLControl-Rx) is the more informative measure. We conducted a systematic review of large-scale trials of statins versus placebo, usual care or active (lower-dose statin) control to calculate updated summary estimates of risk reduction in coronary heart disease (CHD) and all-cause mortality. Meta-regression analysis was used to ascertain the relations of different LDL-C metrics to outcome. In 20 eligible RCTs, there were significant overall reductions for CHD (OR=0.72, 95% CI=0.67–0.78) and mortality (OR=0.89, 95% CI=0.84–0.94), but with substantial variability in trial results. ΔLDLControl-Rx was the strongest determinant of CHD risk reduction, particularly after excluding active-comparator studies, and was independent of baseline LDL-C. By contrast, baseline LDL-C edged ΔLDLControl-Rx as the strongest determinant of mortality, but neither was significant after exclusion of active-comparator studies. Exclusion of 3 RCTs involving distinct populations, however, rendered ΔLDLControl-Rx the predominant determinant of mortality reduction. In conclusion, these findings underscore the primacy of absolute reductions in LDL-C to the design and interpretation of RCTs of lipid-lowering therapies, and to framing treatment recommendations based on the proven coronary benefits of these drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.amjcard.2009.12.051

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 52

Metadata

Authors
Kizer, J. R., Madias, C., Wilner, B., Vaughan, C. J., Mushlin, A. I., Trushin, P., Gotto, A. M., & Pasternak, R. C.
Venue
The American Journal of Cardiology
Publisher
Elsevier BV
Published
2010-05
Volume
105
Issue
9
Pages
1289-1296
ISSN
0002-9149 (ISSN-L)
OpenAlex
W1987109158
Cited by
52
References
10
FWCI
9.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relation of Different Measures of Low-Density Lipoprotein Cholesterol to Risk of Coronary Artery Disease and Death in a Meta-Regression Analysis of Large-Scale Trials of Statin Therapy. https://app.cochat.ai/papers/10.1016/j.amjcard.2009.12.051
The paper
Kizer, J. R., Madias, C., Wilner, B., Vaughan, C. J., Mushlin, A. I., Trushin, P., Gotto, A. M., & Pasternak, R. C. (2010). Relation of Different Measures of Low-Density Lipoprotein Cholesterol to Risk of Coronary Artery Disease and Death in a Meta-Regression Analysis of Large-Scale Trials of Statin Therapy. The American Journal of Cardiology. https://doi.org/10.1016/j.amjcard.2009.12.051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.